BOSTON--(BUSINESS WIRE)--NMT Medical, Inc. (NASDAQ: NMTI) announced today that the Company has completed patient enrollment in its pivotal patent foramen ovale (PFO)/stroke clinical trial, CLOSURE I. NMT believes it is the first company to complete enrollment of a prospective, multi-center, randomized, controlled study that examines the potential relationship between PFO and stroke and transient ischemic attacks (TIA). The Company also believes it will be first to submit a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the PFO/stroke and TIA indication.
